AstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data Wins

I am initiating AstraZeneca at a "Strong Buy," driven by robust Q1 2026 revenue growth and portfolio momentum. The company's Oncology and Rare Disease segments delivered 16% and 15% growth, powered by IMFINZI and ULTOMIRIS, respectively. Positive phase 3 data for IMFINZI in unresectable HCC and ULTOMIRIS in IgAN unlock significant expansion opportunities.